(2E)-3-(Dimethylamino)-1-(4-Pyridinyl)-2-Propen-1-One → Imatinib Impurity 38
Reaktionsgleichung
CN(C)/[CH:3]=[CH:4]/[C:5]([C:7]1[CH:12]=[CH:11][N:10]=[CH:9][CH:8]=1)=O.[N+]([O-])(O)=O.[CH3:18][C:19]1[CH:24]=[CH:23][C:22]([N+:25]([O-:27])=[O:26])=[CH:21][C:20]=1[NH:28][C:29]([NH2:31])=[NH:30]>>[CH3:18][C:19]1[CH:24]=[CH:23][C:22]([N+:25]([O-:27])=[O:26])=[CH:21][C:20]=1[NH:28][C:29]1[N:31]=[C:5]([C:7]2[CH:12]=[CH:11][N:10]=[CH:9][CH:8]=2)[CH:4]=[CH:3][N:30]=1Komponenten
3
Versuchsvorschrift
The title compound was prepared by condensation reaction between (2E)-3-(dimethylamino)-1-pyridin-4-ylprop-2-en-1-one and N-(2-methyl-5-nitrophenyl)guanidine nitrate, according to the procedure described in Step C of EXAMPLE 8. MS (M+1)=308.11.
Quellen und Nachweise
- ORD-Eintrag
- ord-91220e99f455473f8c17c74ee0d33828
- Quelldatensatz
- uspto-grants-2014_04
- Patentnummer